Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment for children and young people news

Show

From To
Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

"Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

Published
07 July 2019
From
Medscape (free registration required)
Biktarvy Approved to Treat Pediatric Patients With HIV-1

he Food and Drug Administration (FDA) has approved updated labeling for Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide; Gilead) to include treatment of both adult and pediatric patients weighing at least 25kg with HIV-1 who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Previously, the combination therapy had only been approved for adults.

Published
20 June 2019
From
Monthly Prescribing Reference
U.S. Revises Pediatric HIV Treatment Guidelines

Changes include new information about risks associated with Tivicay during pregnancy and a removal of older drugs owing to toxicities.

Published
23 April 2019
From
Poz
Hepatic steatosis common in young adults with life-long HIV

Thirty-three percent of young adults with HIV since birth or early childhood have hepatic steatosis, a prevalence comparable to older adults with HIV and “significantly higher” than HIV-negative controls, according to research published in The Journal of Infectious Diseases

Published
26 March 2019
From
Healio
Weight Monitoring Key to Pediatric ART Dosing in Resource-Limited Countries

Study findings in a short communication published in HIV Medicine revealed that a large percentage of children living with HIV were prescribed inappropriate doses of antiretroviral therapy (ART) at a pediatric outpatient clinic at Harare Central Hospital in Zimbabwe.

Published
27 February 2019
From
Infectious Disease Advisor
Efavirenz and psychological performance in children living with HIV

Efavirenz remains a clinically effective and relevant antiretroviral drug for people living with HIV – but adverse side effects need to be screened for and monitored in children.

Published
15 February 2019
From
AVERT
UNAIDS, UNICEF and WHO urge countries in western and central Africa to step up the pace in the response to HIV for children and adolescents

At a high-level meeting in Dakar, Senegal, UNAIDS, the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO) urged countries in western and central Africa to do more to stop new HIV infections among children and adolescents and increase HIV testing and treatment coverage. 

Published
16 January 2019
From
UNAIDS press release
Children, HIV and AIDS: The world today and in 2030

The world pledged to end AIDS by 2030. While we have seen remarkable progress in the past decade among children aged 0-9 years, adolescents have been left behind in HIV prevention efforts. A staggering 360,000 adolescents are projected to die of AIDS-related diseases between 2018 and 2030 without additional investment in HIV prevention, testing and treatment programs.

Published
30 November 2018
From
UNICEF
Pharmaceutical corporations are failing children with HIV

One year ago, pharmaceutical corporations committed to improving access to paediatric versions of HIV drugs for children, but very little progress has been made. MSF urges pharmaceutical corporations including Viiv and Merck to immediately register paediatric ARVs and improve access for kids.

Published
30 November 2018
From
Médecins Sans Frontières (MSF)
MSF: Pharmaceutical corporations failing children with HIV

Developing countries are struggling to provide HIV-positive children with World Health Organization (WHO)-recommended treatments because pediatric versions of HIV medicines don’t exist, are priced out of reach, or haven’t been registered in all countries that need them, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ahead of a Vatican City meeting of HIV stakeholders on scaling up diagnosis and treatment for children.

Published
29 November 2018
From
Doctors Without Borders
← First12345...14Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.